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Objective: To compare the performance of the recently developed Swedish experience-based time trade-off (TTO)
valuation of the EuroQol-5D-3L (EQ-5D-3L) against the hypothetical-based TTO valuations from UK, US, Germany
and Denmark.
Methods: Type 2 diabetes patients from the Swedish National Diabetes Register (N = 1 757) responded to EQ-5D-3L
questionnaire in 2008. Health utilities were compared using a range of parametric and nonparametric tests.
Absolute agreement and consistency were investigated using intra-class correlations coefficients (ICCs) and Bland-
Altman plots. Differences in health utilities between known-groups were evaluated. Transition scores for pairs of
observed EQ-5D-3L health states were calculated and compared.
Results: The Swedish tariff (SWT) resulted in substantially higher health utilities and differences were more profound for
more severe health problems. ICC ranged 0.6 to 0.8 and Bland-Altman plots showed wide limits of agreement. While all
tariffs discriminate between known-groups, the effect sizes were generally small. The SWT had higher (lower) known-
group validity for macrovascular (microvascular) complications. The SWT and UK tariff were associated with the lowest
and the highest mean absolute transition scores, respectively, for 2775 observed pairs of the EQ-5D-3L health states.
Conclusion: There were systematic differences between the SWT and tariffs from other countries meaning that
the choice of tariff might have substantial impact on funding decisions. The Swedish experienced-based TTO
valuation will give higher priority to life-extending interventions than those which improve quality of life. We
suggest that economic evaluations in Sweden include both Swedish experience-based and non-Swedish
hypothetical-based valuations through a sensitivity analysis.Introduction
Given the limited health resources, informed and transpar-
ent decision-making becomes increasingly important for
health systems worldwide, and there has been a growing
interest in application of economic evaluation as a tool to
aid informed decision-making for health resources alloca-
tion. Cost-utility analysis is a method of economic evalu-
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From a health economics perspective, a preference-based
measure of HRQoL is required to estimate health-state
scores and calculate quality-adjusted life years (QALYs).
Type 2 diabetes is a costly chronic disease with a growing
prevalence worldwide [1]. In response to this, there has
been a growing interest in evaluating HRQoL in type 2 dia-
betes [2, 3]. Among different disease-specific and generic
measure of health outcomes, the EQ-5D-3L instrument
[4] is a widely used preference-based outcome measure in
the type 2 diabetes context. Recent studies suggested that
the EQ-5D-3L has reasonable validity, reliability and re-
sponsiveness in type 2 diabetes [2, 5]. The EQ-5D-3L is
based on five attributes: mobility, self-care, usual activities,e is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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three levels: no problems, some problems, and severe prob-
lems, resulting in 243 (35) possible health states [4]. Each
health state is assigned an index score by applying scores
from preference weights (tariffs). These tariffs can be de-
rived from two sources: 1) individuals who actually are in
the health state (experience-based valuation), and 2) a gen-
eral population sample (hypothetical-based valuation).
Previous studies generally reported that the experience-
based valuation resulted in higher values than hypothetical-
based valuation [6, 7]. The arguments for and against using
these valuation methods have been previously discussed
[8–10]. Until developing the Swedish experience-based
time trade-off (TTO) value set for EQ-5D-3L [11], the UK
hypothetical-based TTO value set [12] has been the most
commonly used in Sweden. While the choice of valuation
method is a normative choice and depends on decision
context, the empirical consequences of this choice are of
interest as it might have critical impact on resource alloca-
tion decisions [13, 14]. To our best knowledge, only a pre-
vious study compared the newly developed Swedish tariff
with the UK tariff in patients undergoing total hip replace-
ment in Sweden and found that the Swedish tariff was valid
for these patients [15].
In the current study, we used the responses to the EQ-
5D-3L in a large sample of Swedish patients with type 2
diabetes to compare the Swedish experienced-based TTO
valuation with hypothetical-based TTO valuations from
four other countries. In our study, we answered whether
the choice of TTO value sources (i.e., experienced versus
hypothetical) generate any differences in health state’s util-
ity and related health gain/loss. This is an important ques-
tion since presence of any difference can have crucial
impact on cost-utility analyses and funding decisions.
Method and material
Data
The data used in this study was collected through a cross-
sectional survey conducted by the Swedish National Dia-
betes Register (NDR) in 2008 (IQ3 project). The Swedish
version of the EQ-5D-3L was used to collect data on
HRQoL among patients registered in the NDR (the visual
analogue scale section of the EQ-5D-3L was not used in
the survey). Twenty-six primary health care centres partic-
ipated in the IQ3 project and all patients who visited one
of these centres during the recruitment period (1 February
to 30 May 2008) were selected to participate, as long as
they met the inclusion criteria: (1) aged 18–80 years; (2)
time since diagnosis longer than 6 months; and (3) not liv-
ing under a protected identity. More details on the IQ3
project including sample selection have been previously
presented [16]. In the current study, data on 1,757 type 2
diabetes patients who consent to participate in the study
was used. Data on type 2 diabetes-related microvascular(i.e., kidney disorders and retinopathy) and macrovascular
(i.e., acute myocardial infarction, heart failure, non-acute
ischaemic heart disease, and stroke) complications were
retrieved by data linkage with the Swedish Cause of Death
and Hospital Discharge Registers. Ethical approval for the
study was given by the Regional Ethical Review Board of
Gothenburg, Sweden.
Statistical analysis
The EQ-5D-3L index scores for each subject were calcu-
lated using tariffs from Sweden (SWT) [11], UK (UKT)
[12], US (UST) [17], Denmark (DT) [18], and Germany
(GT) [19]. The mean differences between tariffs were tested
using one-way analysis of variance (ANOVA), followed by
post-hoc Bonferroni tests. A minimal clinically important
difference (MCID) was defined as a difference of at least
0.074 between the EQ-5D-3L tariffs based on the UKT
[20]. The median and distribution of the tariffs were com-
pared using Wilcoxon matched-pairs signed-ranks tests.
Agreement between the SWT and other tariffs was evalu-
ated using Bland-Altman plots [21] and intra-class correl-
ation coefficients (ICCs) [22]. The ICCs were estimated
using two-way random effect models. Agreement was con-
sidered poor for ICC values less than 0.40, fair for values
between 0.40 and 0.59, good for values between 0.60 and
0.74, and excellent for values between 0.75 and 1.0 [23].
We also compared the tariffs in terms of ranking observed
EQ-5D-3L health states using Spearman’s rank correlation.
To test for presence of any trend between severity of
health state and difference between the SWT and other tar-
iffs, the observed EQ-5D-3L health states were ranked and
divided in five quintiles based on the UKT and Cuzick’s test
was used to detect any significant trend [24]. We measured
the absolute mean transition score in EQ-5D-3L index
scores for observed pairs of EQ-5D-3L health states. This
absolute transition score measures the health utility gained
for a transition from a worse health state to a better health
state [25]. These scores were compared using one-way
ANOVA and post-hoc Bonferroni tests. In addition, we
assessed the consistency of the tariffs in predicting a posi-
tive (health gain) or negative (health loss) transition scores
for observed pairs of EQ-5D-3L health states. Responsive-
ness of the tariffs to these consistent health transitions was
assessed using standardized response mean (SRM). For this,
we considered a health state with lower EQ-5D-3L score as
the baseline and the one with higher score as the post-
treatment health states [25]. The SRM was calculated as
the post-treatment mean minus the baseline mean di-
vided by the standard deviation of the change. In addition,
to assess clinical importance of the differences between
transition scores by different tariffs, we computed the ab-
solute mean differences of transition scores between SWT
and other countries and compared it with the MCID of
EQ-5D-3L.
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paring the mean EQ-5D-3L index scores between groups
with expected health differences. The significance of any
difference was tested using t-tests. The effect size was com-
puted as the difference between the mean of two known-
groups, divided by the pooled standard deviation. An effect
size of 0.2, 0.5, and 0.8 were considered as small, moderate,
and large, respectively [26]. Then, we compared relative ef-
ficiency of the tariffs in discriminating between groups by
calculating the ratio of the squares of these t-statistics
(using the SWT as reference). Relative efficiencies lower
(greater) than 1 show that the SWT had a greater (lower)
ability in discriminating between known-groups. All ana-
lyses were performed in Microsoft Excel and STATA 13
(StataCorp LP, College Station, TX, USA).
Results
The mean (SD) age of the subjects was 66.1 (8.8) years,
43 % were women, and 82 % had a BMI > 25 kg/m2. The
prevalence of microvascular and macrovascular complica-
tions were 5 % and 24 %, respectively. The results showed
that except for pain, for all other EQ-5D-3L questionnaire
attributes, most patients reported no problems. 593 (34 %)
subjects reported no problems on all five attributes and
three (0.2 %) reported severe problems on all five attri-
butes. The SWT and UKT resulted in the greatest and the
smallest mean values, respectively (Table 1). The results of
one-way ANOVA showed that the mean EQ-5D-3L index
scores were significantly different across tariffs (P < 0.001).
The mean difference (95 % CI) between the SWTand other
tariffs were as follows: UKT 0.11 (0.10-0.12), GT 0.02
(0.02-0.03), UST 0.05 (0.04-0.05), and DT 0.08 (0.07-0.08).
Post-hoc Bonferroni tests revealed that all these differences
were statistically significant (P < 0.001 for the UKT, UST
and DT and P = 0.021 for GT). The proportions of individ-
uals with an absolute mean difference greater than the
MCID in comparing the SWT with other tariffs were: 56 %
with UKT, 35 % with UST, 54 % with DT, and 30 % with
GT.
Figure 1 shows the distribution of the EQ-5D-3L scores
using different tariffs. The SWT and GT did not show any
gap between full health and the second best health state.
The distribution of SWT was significantly different than
the UKT, UST and DT (P < 0.001), but not GT (P = 0.16).Table 1 The EQ-5D-3L index scores predicted by different
tariffs
Country Mean 95 % CI Median Q25 Q75 Range
Sweden 0.88 0.87-0.88 0.91 0.81 0.97 0.34-0.97
UK 0.77 0.76-0.78 0.80 0.71 1 −0.59-1
US 0.83 0.82-0.83 0.83 0.78 1 −0.11-1
Denmark 0.80 0.79-0.81 0.82 0.72 1 −0.62-1
Germany 0.86 0.85-0.87 0.89 0.79 1 −0.21-1In addition, comparing the medians these tariffs using
Wilcoxon matched-pairs signed tests showed that the ST
had the greatest median (P < 0.001).
The Bland-Altman plots (Fig. 2) showed wide limits of
agreement for each pair-wise comparison. More than
92 % of the differences in individual health utility scores
fell within the 95 % limits of agreement between the
SWT and other tariffs. A systematic variation was ob-
served, with a decreasing trend in the mean differences
as the average EQ-5D-3L index score increased. Abso-
lute agreement between the SWT and other tariffs was
generally good with an ICC (95 % CI) of 0.60 (0.29-0.75)
with UKT, 0.80 (0.62-0.88) with UST, 0.72 (0.42-0.85)
with DT, and 0.74 (0.71-0.77) with GT. Although Spear-
man’s rank correlations between the tariffs in ranking
the observed health states were high and statistically sig-
nificant (p > 0.75, P < 0.001; Table 2), the correlations for
the SWT were the smallest ones.
In total, 75 of 243 the possible EQ-5D-3L health states
were observed in our study sample. Five health states
(11111, 11121, 11122, 11112, and 21121) accounted for
71 % of health states reported by the respondents. While
the SWT did not result in any negative score, there was at
least one health state with a negative score using other tar-
iffs (13 UKT, 1 UST, 1 GT, and 5 DT). While the UKT and
UST resulted in unique scores for every health states, there
were ties (i.e., health states with the same EQ-5D-3L index
scores) for other tariffs with the highest frequency for GT.
Figure 3 displays mean difference between the SWT
and other tariffs across five quintiles of observed health
states ranked by the UKT. In almost all quintiles the SWT
resulted in the greatest mean index scores (only in least
severe health states, mean index scores for GT was great-
est). There was an increasing trend between severity of
health state and difference between the SWT with other
tariffs and Cuzick’s test confirmed this (Z ranged 6.29 to
7.86, P < 0.001). Across these health states, the SWT re-
sulted in smaller scores for 3, 6, 1, and 16 health states
compared with UKT, UST, DT and GT, respectively.
The 75 observed health states resulted in 2,775 pairs
of health states (2C75). One-way ANOVA and post-hoc
Bonferroni tests showed that the SWT and UKT were
associated with the lowest and the highest mean abso-
lute transition scores for these 2,775 pairs (Table 3). In
2,078 of 2,775 (74.9 %) pairs of the EQ-5D-3L health
states, the five tariffs were consistent in predicting health
gain/loss regardless of the magnitude of the gain/loss. In
addition, the SWT had the lowest and the highest
consistency with GT and DT, respectively. In 1,543 of the
2,078 (74.3 %) of consistent transitions, the SWT had the
smallest magnitude of gain/loss. For these consistent health
transitions, SRM ranged from 1.56 to 1.81 with the lowest
values for GT and SWT. A substantial proportion of differ-
ences in transition scores between SWT and other tariffs
Fig. 1 Distribution of EQ-5D-3L scores from different tariffs among type 2 diabetes patients
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scores >MCID).
Statistically significant differences (P < 0.05) were found
for most between-group comparisons using all tariffs
(Table 4). The SWT was the only one, which was not
sensitive to modality of treatment. Most effect sizes were
small and the relative efficiencies showed that the SWT
generally had higher (lower) discriminative ability for
macrovascular (microvascular) complications compared to
other tariffs.
Discussion
In the current study, we compared the Swedish
experienced-based TTO valuation of EQ-5D-3L against
hypothetical-based TTO valuations from the UK, US,
Germany and Denmark in a large sample of Swedish type2
diabetes patients. We found wide limits of agreement be-
tween the SWT and other tariffs. The Swedish EQ-5D-3L
index scores were meaningfully higher than scores pro-
duced using other tariffs. Examining the possible health
transitions in our study sample revealed that the SWT, on
average, would lead to smaller changes in QALYs.
The ceiling effect observed in our study is a common
feature of the EQ-5D-3L questionnaire [27], implying
that the EQ-5D-3L is not able to capture variations
among patients in mild health states [28]. While the EQ-
5D-3L was able to discriminate between known-groups,
the effect sizes were small suggesting that the EQ-5D-3L
might have limited discriminative ability among Swedish
patients with type 2 diabetes. Moreover, there weredifferences between the tariffs in term of discriminative
ability; and the Swedish tariff was insensitive to the modal-
ity of treatment. Lower sensitivity of experienced-based
valuation was previously reported [13].
The SWT generally lead to smaller changes in QALYs,
which translate into greater and less favourable incre-
mental cost-effectiveness ratios (ICERs) compared to the
other tariffs. This results from the fact that the SWT has
a much narrower range than the other tariffs. There is
no health state with a value close to or below zero using
the SWT; the most severe health state (33333) has a util-
ity score of 0.340. This implies that using the SWT likely
result in a smaller estimates of effectiveness of interven-
tions that substantially improve HRQoL among patients
with most severe health states. In addition, higher values
attached to impaired health states from the Swedish
experienced-based TTO valuation result in higher utility
gain from life-extending interventions and lower utility
gain from quality of life-improving measures. This im-
plies that applying the SWT in place of the hypothetical-
based TTO valuations from other countries will result in
more favourable ICERs for life-extending interventions
and less favourable ICERs for quality of life-improving
interventions [29]. Of course, there are health transitions
where the SWT would be resulted in greater gains in
QALYs and smaller ICERs. For example, in 270 (11.5 %)
of 2345 consistent health transitions between the SWT
and UKT in our study, the SWT would result in greater
gain and lower ICERs. It should be noted that although we
compared the Swedish experience-based tariff with other
Fig. 2 Bland-Altman plots of EQ-5D-3L scores for type 2 diabetes patients
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tariff may not be used to construct conventional QALYs
because it does not include death as a health state [14].
Whether the different ICERs produced by the SWT
compared with the other tariffs resulted in discrepant deci-
sion funding depends on several factors including efficacies
of interventions, the severity of the health states, the distri-
bution of health transitions, cost difference between inter-
vention and the willingness to pay (WTP) threshold. For
example if we assume a WTP of Swedish Krona (SEK)Table 2 Agreement between the tariffs in ranking the observed
EQ-5D-3L health states measured by Spearman’s rank
correlation




Denmark 0.91*** 0.98*** 0.97***
Germany 0.77*** 0.96*** 0.96*** 0.92***
***p < 0.001500,000 per QALY gained, then if a new intervention is
SEK 1000 more expensive and causes the health transitions
from the health state “23231” to the health state “23222”,
then the ICER applying the SWT and UKT will be SEK
1,428,571 and 5208 per QALY gained, respectively, that
translate into different decision funding. However, in this
example, if the WTP changes to SEK 1,500,000, or cost dif-
ference decline to SEK 100, or the health transition hap-
pens in a minor portion of the sample, then difference in
QALY gained between the SWT and UKT does not result
in discrepant decision funding.
The narrower range of the SWT compared with the
other tariffs might be due to the difference in valuation
method (experienced vs. hypothetical). Previous studies
found that patients generally report higher values than
general population and the difference increased as health
states gets worse [7, 30, 31]. The similar trend was ob-
served in the present study. The differences between
valuation elicited from patient and general population
are attributed to failure to rate the same health state, to
have different measuring rods, and patient adaptation to a
health state [10]. The differences in methodology including
Fig. 3 The mean difference in EQ-5D-3L scores across five quintiles of the observed health states, ranked by the UK tariff
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reason for the observed difference between the SWT and
the other tariffs here. For example, the data for the SWT
was collected by self-administered postal survey while in
other countries interviews were used. Moreover, due to
methodological limitations in the surveys, the SWT did
not allow for negative values which should be taking into
account in any application. Differences induced by transla-
tion and inherent difference in populations (e.g., cultural
norms, socioeconomic status, health status, clinical prac-
tice patterns, access to health care services) might be other
potential explanations of observed difference comparing
the SWT with the other tariffs [32].
The results of the current study should be interpreted in
light of some limitations. The study was conducted among
people with type 2 diabetes and only 75 (31 %) of 243 the
possible EQ-5D-3L health states were observed. While our
sample demographic and clinical characteristics areTable 3 Absolute transition scores, consistent health transition and
transitions
Absolute mean transition score 95 % CI Consistent hea
ranked by the
(Sweden vs.) (%
Sweden 0.17 0.16-0.17 -
UK 0.40 0.39-0.41 84.5
US 0.26 0.25-0.27 83.4
Denmark 0.33 0.32-0.34 86.8
Germany 0.34 0.33-0.35 77.2
aFor this, first we computed the absolute difference in transition scores between Sw
calculated the proportion of health transitions with absolute difference greater thancomparable with the Swedish type 2 diabetes population
(www.ndr.nu), but possible differences in other characteris-
tics (e.g., socioeconomic status) might limits generalizability
of our findings to all Swedish type 2 diabetes population. In
addition, our finding might not be generalizable to other dia-
betes population or other diseases where the other EQ-5D-
3L health states might be more common. As a consequence
of cross-sectional design of the study and lack of data on
changes in health status over time, we assumed that all
health transitions had the same probability of occurrence
that is not true in reality. In addition, we were not able to
assess the responsiveness to change and test-retest reliability
of the tariffs.
Conclusion
We found that there were substantial and clinically im-
portant differences between the Swedish experienced-






transitions (n = 2078)
Clinically important difference







eden and other countries for all 2775 possible health transitions. Then, we
0.074
Table 4 Known-group validity of the EQ-5D-3L tariffs
Sweden UK US Denmark Germany
HbA1c≤ 7 (n = 890) 0.88 0.78 0.84 0.82 0.87
HbA1c > 7 (n = 867) 0.87 0.75 0.81 0.79 0.84
Difference 0.01* 0.04** 0.02** 0.03** 0.03**
Relative efficiency 1.00 1.29 1.25 1.37 1.25
Effect size 0.12 0.14 0.13 0.14 0.13
BMI < 30 (n = 991) 0.89 0.79 0.84 0.82 0.87
BMI≥ 30 (n = 766) 0.86 0.74 0.80 0.78 0.83
Difference 0.03*** 0.06*** 0.04*** 0.05*** 0.04***
Relative efficiency 1.00 0.98 0.97 1.01 0.90
Effect size 0.22 0.22 0.22 0.22 0.21
Diabetes duration ≤ 8 (n = 929) 0.88 0.78 0.84 0.81 0.87
Diabetes duration > 8 (n = 828) 0.87 0.75 0.81 0.79 0.84
Difference 0.01** 0.04** 0.02** 0.03** 0.03**
Relative efficiency 1.00 1.15 1.14 1.09 1.36
Effect size 0.13 0.14 0.13 0.13 0.15
Age ≤ 67 (n = 929) 0.88 0.77 0.83 0.80 0.86
Age > 67 (n = 828) 0.87 0.76 0.82 0.80 0.85
Difference 0.01 0.01 0.01 0.01 0.01
Relative efficiency 1.00 0.41 0.81 0.41 0.84
Effect size 0.06 0.04 0.05 0.04 0.05
Microvascular complications (No) (n = 1670) 0.88 0.77 0.83 0.80 0.86
Microvascular complications (Yes) (n = 87) 0.83 0.66 0.75 0.72 0.77
Difference 0.05*** 0.11*** 0.08*** 0.08*** 0.09***
Relative efficiency 1.00 1.06 1.09 0.93 1.17
Effect size 0.42 0.43 0.44 0.40 0.45
Macrovascular complications (No) (n = 1332) 0.89 0.79 0.84 0.82 0.87
Macrovascular complications (Yes) (n = 425) 0.84 0.70 0.78 0.75 0.80
Difference 0.04*** 0.08*** 0.06*** 0.06*** 0.07***
Relative efficiency 1.00 0.76 0.78 0.69 0.85
Effect size 0.37 0.32 0.32 0.31 0.34
Myocardial infarction (No) (n = 1581) 0.88 0.77 0.83 0.81 0.86
Myocardial infarction (Yes) (n = 176) 0.85 0.71 0.79 0.76 0.81

















Table 4 Known-group validity of the EQ-5D-3L tariffs (Continued)
Relative efficiency 1.00 0.81 0.88 0.86 0.71
Effect size 0.26 0.23 0.24 0.24 0.22
Stroke (No) (n = 1643) 0.88 0.77 0.83 0.81 0.86
Stroke (Yes) (n = 114) 0.82 0.66 0.75 0.72 0.76
Difference 0.06*** 0.12*** 0.09*** 0.09*** 0.10***
Relative efficiency 1.00 0.71 0.79 0.65 0.78
Effect size 0.54 0.45 0.48 0.44 0.47
Heart failure (No) (n = 1673) 0.88 0.77 0.83 0.81 0.86
Heart failure (Yes) (n = 84) 0.82 0.65 0.74 0.71 0.75
Difference 0.06*** 0.13*** 0.09*** 0.10*** 0.11***
Relative efficiency 1.00 0.82 0.79 0.74 0.93
Effect size 0.54 0.49 0.48 0.47 0.52
Non-acute IHD (No) (n = 1533) 0.88 0.78 0.83 0.81 0.86
Non-acute IHD (Yes) (n = 224) 0.84 0.70 0.78 0.75 0.80
Difference 0.04*** 0.07*** 0.05*** 0.06*** 0.06***
Relative efficiency 1.00 0.84 0.80 0.78 0.89
Effect size 0.31 0.29 0.28 0.27 0.29
Kidney disorders (No) (n = 1710) 0.88 0.77 0.83 0.80 0.86
Kidney disorders (Yes) (n = 47) 0.82 0.61 0.72 0.69 0.73
Difference 0.06*** 0.16*** 0.11*** 0.12 0.13***
Relative efficiency 1.00 1.28 1.33 1.13 1.43
Effect size 0.54 0.61 0.62 0.57 0.64
Retinopathy (No) (n = 1719) 0.88 0.77 0.83 0.80 0.86
Retinopathy (Yes) (n = 38) 0.84 0.69 0.77 0.74 0.80
Difference 0.04 0.08 0.06 0.06 0.06
Relative efficiency 1.00 0.85 0.98 0.79 0.82
Effect size 0.32 0.29 0.32 0.28 0.29
Insulin treatment (No) (n = 901) 0.88 0.78 0.84 0.81 0.87
Insulin treatment (Yes) (n = 856) 0.87 0.75 0.82 0.79 0.84
Difference 0.01 0.03* 0.02* .02* 0.03**
Relative Efficiency 1.00 2.08 1.90 1.59 3.08
Effect size 0.08 0.11 0.11 0.10 0.14
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ences were larger for more severe health states. This find-
ing and also wide limits of agreement between the tariffs
suggest that choice of tariff might have important impact
on economic evaluation studies and funding decisions.
We did not aim to answer the question of which valuation
(experienced or hypothetical) should be used to health
state for cost utility analyses. However, if based on recom-
mendation by the Swedish Dental and Pharmaceutical
Benefits Agency, the Swedish experienced-based TTO valu-
ation is used in cost-utility analyses, we suggest that the
hypothetical-based TTO valuation should be applied in a
sensitivity analysis and the impact on the finding should be
discussed. Further analyses are needed to explore the fac-
tors contributed in the observed differences in the present
study. Comparing different tariffs in a longitudinal
study, the influence of differences between tariffs on
health studies including economic evaluation and inequal-
ity, and differences in EQ-5D-5L tariffs whenever the
Swedish EQ-5D-5L value set become available are subjects
for future studies.
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